These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8024198)

  • 1. H-ras ribozyme-mediated alteration of the human melanoma phenotype.
    Ohta Y; Tone T; Shitara T; Funato T; Jiao L; Kashfian BI; Yoshida E; Horng M; Tsai P; Lauterbach K
    Ann N Y Acad Sci; 1994 May; 716():242-53; discussion 253-6. PubMed ID: 8024198
    [No Abstract]   [Full Text] [Related]  

  • 2. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells.
    Ohta Y; Kijima H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
    Nucleic Acids Res; 1996 Mar; 24(5):938-42. PubMed ID: 8600463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes.
    Ohta Y; Kijima H; Kashani-Sabet M; Scanlon KJ
    J Invest Dermatol; 1996 Feb; 106(2):275-80. PubMed ID: 8601728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of the malignant phenotype by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
    Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribozyme as an approach for growth suppression of human pancreatic cancer.
    Kijima H; Scanlon KJ
    Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
    Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.
    Feng M; Cabrera G; Deshane J; Scanlon KJ; Curiel DT
    Cancer Res; 1995 May; 55(10):2024-8. PubMed ID: 7743496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer.
    Irie A; Anderegg B; Kashani-Sabet M; Ohkawa T; Suzuki T; Halks-Miller M; Curiel DT; Scanlon KJ
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):341-9. PubMed ID: 10463078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype.
    Albino AP; Nanus DM; Mentle IR; Cordon-Cardo C; McNutt NS; Bressler J; Andreeff M
    Oncogene; 1989 Nov; 4(11):1363-74. PubMed ID: 2682463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
    Tsao H; Zhang X; Fowlkes K; Haluska FG
    Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping.
    Thiede C; Bayerdörffer E; Blasczyk R; Wittig B; Neubauer A
    Nucleic Acids Res; 1996 Mar; 24(5):983-4. PubMed ID: 8600471
    [No Abstract]   [Full Text] [Related]  

  • 12. [Ribozyme targeted the point-mutation of activated oncogene inhibits its expression in vivo].
    Liu G; Chen Y; Zhao X; Dong Y; Chen D
    Yi Chuan Xue Bao; 1996; 23(6):477-85. PubMed ID: 9084224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways.
    Wang CH; Tsai LJ; Tsao YP; Hsieh JT; Chien WW; Liao CL; Wang HW; Liu HS; Chen SL
    Biochem Biophys Res Commun; 2002 Nov; 298(5):805-14. PubMed ID: 12419327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of EJ cells tumorigenicity.
    Tone T; Kashani-Sabet M; Funato T; Shitara T; Yoshida E; Kashfian BI; Horng M; Fodstadt O; Scanlon KJ
    In Vivo; 1993; 7(6A):471-6. PubMed ID: 8193263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells.
    Funato T; Ishii T; Kambe M; Scanlon KJ; Sasaki T
    Cancer Gene Ther; 2000 Mar; 7(3):495-500. PubMed ID: 10766356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer.
    Kijima H; Yamazaki H; Nakamura M; Scanlon KJ; Osamura RY; Ueyama Y
    Int J Oncol; 2004 Mar; 24(3):559-64. PubMed ID: 14767540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibited neoplastic phenotype by the c-Ha-ras antisense RNA.
    Lu GR; Wu CJ; Ke Y; Xiong X; Li YJ; Liu JM; Xu Y; Xu W; Li JY; Deng GR
    Sci China B; 1991 Dec; 34(12):1485-91. PubMed ID: 1801843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammerhead ribozyme.
    Bi F; Fan D; Hui H; Wang C; Zhang X
    Cancer Gene Ther; 2001 Nov; 8(11):835-42. PubMed ID: 11773973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells.
    Tsuchida T; Kijima H; Oshika Y; Tokunaga T; Abe Y; Yamazaki H; Tamaoki N; Ueyama Y; Scanlon KJ; Nakamura M
    Biochem Biophys Res Commun; 1998 Dec; 253(2):368-73. PubMed ID: 9878544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
    Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
    Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.